HHS’ need for R&D speed; weird GLP-1 side effects

HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs. 

By PharmaVoice Staff • Oct. 9, 2026

A day in the life of a Merck R&D chief

Dr. Eliav Barr pulls back the curtain on what it's like to manage Merck’s fast-growing pipeline.

By Meagan Parrish • Oct. 9, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

5 key facts about the FDA expedited IND pilot program

The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

By Kelly Bilodeau • Oct. 7, 2026

Top pharma industry conferences in 2027

Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.

By Meagan Parrish • Oct. 6, 2026

The next frontier in obesity drugs: lasting weight loss

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

By Kelly Bilodeau • Oct. 6, 2026

Will there be more to Daiichi’s story than DXd ADCs?

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its DXd franchise.

By Meagan Parrish • Oct. 5, 2026

Roche’s AI lab; Biohaven’s pivotal pause

Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven

By PharmaVoice Staff • Oct. 2, 2026

3 drug targets pharma is betting on next

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

By Alexandra Pecci • Oct. 2, 2026

Are psychedelics as effective as trials suggest?

Patients often know when they’ve received a psychedelic, potentially distorting trial results. Researchers are testing new ways to make those studies more reliable.

By Kelly Bilodeau • Oct. 1, 2026

Beam sues 2 biotechs, alleging theft of base editing trade secrets

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

By Gwendolyn Wu • Sept. 30, 2026

An AI agent made a tiny drug R&D mistake. Then it kept going.

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?

By Sy Mukherjee • Sept. 30, 2026

Epilepsy R&D is breaking out of its old playbook

Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially disease-modifying treatments.

By Kelly Bilodeau • Sept. 29, 2026

Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next

Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.

By Alexandra Pecci • Sept. 25, 2026

Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry

Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...

By PharmaVoice Staff • Sept. 25, 2026

What J&J’s Spravato patent win could mean for psychedelic drugs

As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.

By Kelly Bilodeau • Sept. 24, 2026

Novo talks up drug launches in effort to win back investors

At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

By Jonathan Gardner • Sept. 23, 2026

Lilly stopped showing its phase 1 pipeline. Is it playing R&D chess?

Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.

By Sy Mukherjee • Sept. 23, 2026

CRO consolidation keeps rolling. What does that mean for pharma?

While M&A expands one-stop shop capabilities at large CROs, pharma companies could face tradeoffs around niche expertise and service continuity.

By Alexandra Pecci • Sept. 22, 2026

A norovirus breakthrough?; another women’s healthtech haul

Yale researchers untangled norovirus RNA and Evvy just pulled in $40 million for precision medicine in women's health.

By PharmaVoice Staff • Sept. 18, 2026

A dark horse in the orexin race?

As the orexin competition heats up in the neuroscience space, Harmony Biosciences is developing an early-stage asset it believes could have an edge over rivals.

By Meagan Parrish • Sept. 18, 2026

Sling banks $123M for an experimental thyroid eye disease pill

A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

By Gwendolyn Wu • Sept. 17, 2026

8 biotech IPO prospects testing investor appetite

Fresh filings and older proposals reveal different tests of clinical evidence, financing needs and readiness for public ownership.

By Sy Mukherjee • Sept. 17, 2026

‘Patients are not a renewable resource’: Rethinking rare disease R&D

Small patient communities face repeated demands for samples, data and time. The Speak Foundation’s founder explains how pharma can ease that burden while strengthening patients’ R&D involvement.

By Alexandra Pecci • Sept. 16, 2026

Where female participation in clinical trials has caught up — and where gaps remain

Getting more women into drug R&D remains critical for boosting health outcomes. But in some disease areas, pharma is still falling behind.

By Kelly Bilodeau • Sept. 16, 2026

3 KRAS drugs to watch as the field expands

Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.

By Kelly Bilodeau • Sept. 15, 2026